Fresh analysis indicates that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional diet and exercise regimens.
Published data in a prominent medical journal shows that while overweight people can lose a large proportion of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users using these drugs should be aware of the risk of fast weight regain when the medication ends," stated researcher Dr. Susan Jebb.
Such speed of recovery means a return to original weight within about a year and a half.
Analyzing Therapies
The study, which reviewed dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through diet and exercise typically have a more gradual weight regain—around 0.1 kg a month—once they finish.
Understanding the Quick Regain
Doctors believe the way of the drugs accounts for the amplified weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, due to the high risk of relapse, the therapy might need to be life-long.
This perspective is echoed by drug manufacturers, who say that the findings "emphasize the persistent nature of excess weight," comparing it to managing conditions like diabetes.
User Testimonies
People who have come off the medication explain a sudden return of cravings.
"I experienced a switch flipping and you're instantly extremely hungry," said an individual.
This challenge is compounded if individuals have not adopted permanent dietary or behavioural modifications during treatment.
Significant Use
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and long-term success likely depends on combined lifestyle changes.
